Performance and Safety of Semical Dermal Fillers in Facial Rejuvenation

Exclusion Criteria

• •Patients under 18 years of age
• •Presence of impairment of wound healing or blood flow
• •Known history of allergy to the study product (hyaluronic acid), local anesthetic used (lidocaine) or gran-positive streptococcal proteins
• •Presence or history of keloid formation tendency, hypertrophic scar, shromatosis or discoloration
• •Skin disease with pronounced skin pigmentation
• •Connective tissue disorders
• •Coagulation disorders
• •Existing inflammation / infection at the injection site
• •Frequently recurring facial / labial herpes
• •Permanent or semi-permanent tendon, bone and muscle implants near the area to be application
• •History of allergy in the mouth area
• •Active autoimmune disease or immunosuppressed individuals with immune system problems
• •Diabetes mellitus or uncontrolled systemic disease (endocrine, hepatic, renal, cardiac pulmonary or neurological disorders)
• •Volunteers with acute inflammatory conditions or infections, active herpes infection or history of chronic and recurrent infections
• •Concomitant medications that affect blood circulation (e.g. aspirin, NSAIDs, Vitamin E, topical and systemic corticosteroids, narcotic antidepressants, immunosuppressive drugs; excluding hormonal and contraceptive treatments started before 1 year) and medications and treatments have the potenrial to affect treatment aoutcomes according to the investigator's opinion
• •Known alcohol or drug abuse
• •Subjects who are pregnant or breasfeeding
• •Subjects who have received COVID-19 vaccination within 30 days before dermal filler application
• •Epilepsy or porphyria, congenital or idiopathic methemoglebinemia, or glucose-6-phosphate dehydrogenase deficiency
• •Analgesic dependence or need for continuous use
• •Syphilis or HIV infection
• •Subjects who have undergone medication or surgical treatments that may cause significant changes in body weight after dermal filler application (such as bariatric surgery)